Please login to the form below
DNA damage specialists Artios Pharma raises $84m
Team behind development of Lynparza focus on next-gen DDR inhibitors
Allergan builds on gene editing deal
Firm will co-develop CRISPR candidate for vision-threatening disorder
Regeneron and Bluebird sign $100m cell therapies deal
Six targets chosen from TCR and other cell therapy platforms
Mallinckrodt doses first patient in muscular dystrophy trial
Repurposed drug could help delay decline in muscle function
Daily Brief: Karuna raises $42m for novel CNS approach, Chen exits Roche, Orchard gains GSK board member
The latest from pharma, biotech and healthcare
Nanobiotix signs €40m deal with the EIB
loan to fund innovative nanomedicine platform
Big debate follows Biogen/Eisai’s Alzheimer’s study unveiling
Mixed results prompted a 10% share drop for both companies
GSK two-drug trial in untreated HIV raises Gilead rivalry
Intends to file the combination later this year to challenge Gilead’s Biktarvy
Celgene’s Revlimid gets a win in late-stage lymphoma
Patients on Revlimid and Roche’s Rituxan saw boosted PFS rates
Adopting a creative IP approach towards biotech clusters
Why big pharma paradigm needs to change
-
A unique ecosystem How life science and healthcare clusters are driving innovation
-
Riding the wave of digital disruptionThe challenges and rewards of meeting consumer expectations
-
Daily Brief: Janssen's HIV vaccine, Q2 results, Biogen's Alzheimer's dataNews from pharma, biotech and healthcare
-
Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPOA round up from pharma, biotech and healthcare
-
Vyriad inks immunotherapy alliance with Merck/PfizerGenetically engineered virus produces immune response in tumours
-
Pfizer enters late-stage haemophilia B gene therapy trialRace is on to free patients of regular injections
-
J&J’s Invokana aces diabetic kidney disease trial, setting up filingsIt could be the first new drug in 15 years to slow kidney damage development
-
MaxCyte gets green light for solid tumour cell therapyIts first CAR therapy will be tested in patients with ovarian cancer
-
Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on pricesThe latest from pharma, biotech and healthcare
-
Lilly appoints Maura Dickler as VP of late phase oncology developmentShe will join the pharma firm from the Memorial Sloan Kettering Cancer Center
-
Metrion Biosciences establishes scientific advisory board
The board will provide scientific oversight and strategic advice to Metrion
-
Dr Sotirios Stergiopoulos leaves Shire for IpsenHe becomes the French biopharma’s chief medical officer
-
Linda Law joins Advicenne as US VP, clinical development and med affairsShe will oversee the biopharma’s developments with its dTRA candidate
-
Dr Fiona Marshall heads up MSD's new UK research facility She will be based in London and focus on early bioscience discovery
Latest research appointments
Featured jobs
- Account Director or Senior Account Director
-
Salary TBC
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
starting from £32, 500
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity
- Cancer immunotherapy: What's on the horizon?
- ABPI hits out at ‘punitive’ UK medicines cost controls
- Bluebird’s first gene therapy gets European fast track
- Moving annual total (MAT)
- Your excellent marketing team
- Paramount Recruitment reveals Communiqué Casino winners
- After Cohen payment scandal, Novartis unveils new ethics chief
- Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland
- AI company Sensyne raises £60m in IPO
- Shock as NICE turns down Biogen’s SMA therapy
PMHub
Grace Communications
Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....
Latest intelligence
- Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
- The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
- Londonvelophobia (fear of cycling in London) – debunked
- ...
- How Helpful are Simple Health Messages?
- ...
Quick links
Infographics
